Diagnostic accuracy of sliding sign for detecting pouch of Douglas obliteration and bowel involvement in women with suspected endometriosis: systematic review and meta-analysis

The aim of this systematic review and meta-analysis was to evaluate the diagnostic accuracy of the sliding sign on transvaginal ultrasound (TVS) in detecting pouch of Douglas obliteration and bowel involvement in patients with suspected endometriosis, using laparoscopy as the reference standard

Influência da posição da estaca no ramo ortotrópico na propagação de dois genótipos de Coffea Canephora Pierre irrigados pelo método de microaspersão por nebulização.

O uso de mudas de qualidade é fundamental para assegurar a produtividade das lavouras de café conilon. O uso de estacas provenientes de ramos ortotrópicos é a alternativa mais utilizada. Porém, ainda permanecem questões que devem ser investigadas, relativasa o processo de propagação, pois fatores exógenos e endógenos podem limitar a brotação, mesmo quando as condições sejam favoráveis para este processo. Assim, objetivou-se avaliar a produção de mudas e a taxa fotossintética, a partir de estacas provenientes de três diferentes posições no ramo ortotrópico, ápice, meio e base do ramo ortotrópico em dois genótipos de café conilon (12V e 748). Determinou-se a taxa fotossintética líquida (A-?mol CO2m-2s-1) aos 0, 13, 26 e 39 dias após o plantio das estacas (DAP) e o porcentual de estacas enraizadas e de estacas com brotaçãoque emitiram raiz aos 39 DAP. As curvas ajustadas pela equação de regressão não linear para a taxa fotossintética líquida indica um padrão de aclimatação e recuperação durante a produção de mudas. Não houve influência dos fatores genótipo e posição do ramo na fotossíntese. O genótipo 748 e os terços mediano e basaldo ramo ortotrópico apresentaram melhor enraizamento

Leptin Reduces the Expression and Increases the Phosphorylation of the Negative Regulators of GLUT4 Traffic TBC1D1 and TBC1D4 in Muscle of ob/ob Mice

Leptin improves insulin sensitivity in skeletal muscle. Our goal was to determine whether proteins controlling GLUT4 traffic are altered by leptin deficiency and in vivo leptin administration in skeletal muscle of wild type and ob/ob mice. Leptin-deficient ob/ob mice were divided in three groups: control, leptin-treated (1 mg/kg/d) and leptin pair-fed ob/ob mice. Microarray analysis revealed that 1,546 and 1,127 genes were regulated by leptin deficiency and leptin treatment, respectively. Among these, we identified 24 genes involved in intracellular vesicle-mediated transport in ob/ob mice. TBC1 domain family, member 1 (Tbc1d1), a negative regulator of GLUT4 translocation, was up-regulated (P = 0.001) in ob/ob mice as compared to wild types. Importantly, leptin treatment reduced the transcript levels of Tbc1d1 (P<0.001) and Tbc1d4 (P = 0.004) in the leptin-treated ob/ob as compared to pair-fed ob/ob animals. In addition, phosphorylation levels of TBC1D1 and TBC1D4 were enhanced in leptin-treated ob/ob as compared to control ob/ob (P = 0.015 and P = 0.023, respectively) and pair-fed ob/ob (P = 0.036 and P = 0.034, respectively) mice. Despite similar GLUT4 protein expression in wild type and ob/ob groups a different immunolocalization of this protein was evidenced in muscle sections. Leptin treatment increased GLUT4 immunoreactivity in gastrocnemius and extensor digitorum longus sections of leptin-treated ob/ob mice. Moreover, GLUT4 protein detected in immunoprecipitates from TBC1D4 was reduced by leptin replacement compared to control ob/ob (P = 0.013) and pair-fed ob/ob (P = 0.037) mice. Our findings suggest that leptin enhances the intracellular GLUT4 transport in skeletal muscle of ob/ob animals by reducing the expression and activity of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4

Regulation of Alr1 Mg Transporter Activity by Intracellular Magnesium

Mg homeostasis is critical to eukaryotic cells, but the contribution of Mg transporter activity to homeostasis is not fully understood. In yeast, Mg uptake is primarily mediated by the Alr1 transporter, which also allows low affinity uptake of other divalent cations such as Ni2+, Mn2+, Zn2+ and Co2+. Using Ni2+ uptake to assay Alr1 activity, we observed approximately nine-fold more activity under Mg-deficient conditions. The mnr2 mutation, which is thought to block release of vacuolar Mg stores, was associated with increased Alr1 activity, suggesting Alr1 was regulated by intracellular Mg supply. Consistent with a previous report of the regulation of Alr1 expression by Mg supply, Mg deficiency and the mnr2 mutation both increased the accumulation of a carboxy-terminal epitope-tagged version of the Alr1 protein (Alr1-HA). However, Mg supply had little effect on ALR1 promoter activity or mRNA levels. In addition, while Mg deficiency caused a seven-fold increase in Alr1-HA accumulation, the N-terminally tagged and untagged Alr1 proteins increased less than two-fold. These observations argue that the Mg-dependent accumulation of the C-terminal epitope-tagged protein was primarily an artifact of its modification. Plasma membrane localization of YFP-tagged Alr1 was also unaffected by Mg supply, indicating that a change in Alr1 location did not explain the increased activity we observed. We conclude that variation in Alr1 protein accumulation or location does not make a substantial contribution to its regulation by Mg supply, suggesting Alr1 activity is directly regulated via as yet unknown mechanisms

SMF-1, SMF-2 and SMF-3 DMT1 Orthologues Regulate and Are Regulated Differentially by Manganese Levels in C. elegans

Manganese (Mn) is an essential metal that can exert toxic effects at high concentrations, eventually leading to Parkinsonism. A major transporter of Mn in mammals is the divalent-metal transporter (DMT1). We characterize here DMT1-like proteins in the nematode C. elegans, which regulate and are regulated by Mn and iron (Fe) content. We identified three new DMT1-like genes in C. elegans: smf-1, smf-2 and smf-3. All three can functionally substitute for loss of their yeast orthologues in S. cerevisiae. In the worm, deletion of smf-1 or smf-3 led to an increased Mn tolerance, while loss of smf-2 led to increased Mn sensitivity. smf mRNA levels measured by QRT-PCR were up-regulated upon low Mn and down-regulated upon high Mn exposures. Translational GFP-fusions revealed that SMF-1 and SMF-3 strongly localize to partially overlapping apical regions of the gut epithelium, suggesting a differential role for SMF-1 and SMF-3 in Mn nutritional intake. Conversely, SMF-2 was detected in the marginal pharyngeal epithelium, possibly involved in metal-sensing. Analysis of metal content upon Mn exposure in smf mutants revealed that SMF-3 is required for normal Mn uptake, while smf-1 was dispensable. Higher smf-2 mRNA levels correlated with higher Fe content, supporting a role for SMF-2 in Fe uptake. In smf-1 and smf-3 but not in smf-2 mutants, increased Mn exposure led to decreased Fe levels, suggesting that both metals compete for transport by SMF-2. Finally, SMF-3 was post-translationally and reversibly down-regulated following Mn-exposure. In sum, we unraveled a complex interplay of transcriptional and post-translational regulations of 3 DMT1-like transporters in two adjacent tissues, which regulate metal-content in C. elegans

Perspectives On Premenstrual Syndrome/premenstrual Dysphoric Disorder: Outcomes From A Meeting Of The Latin America Experts Group

Experts in the field of obstetrics and gynecology recently met to discuss issues related to the epidemiology, diagnosis, and treatment of premenstrual syndrome/premenstrual dysphoric disorder (PMS/PMDD) in Latin American countries. The experts reviewed the existing accepted guidelines related to these issues and discussed adaptations to the diagnostic criteria and treatment recommendations in order to meet the specific needs of women in Latin American countries. This manuscript provides an overview of key information presented at this meeting and provides an up-to-date assessment of emerging treatment options covered in existing guidelines and treatment reviews. In addition, we discuss the relevance and possible application of this expanded knowledge to Latin American countries and provide practical recommendations for the diagnosis and management of PMS/PMDD in this setting. © 2007 Adis Data Information BV. All rights reserved.155263277Hylan, T.R., Sundell, K., Judge, R., The impact of premenstrual symptomatology on functioning and treatment seeking behaviour: Experience from the United States, United Kingdom and France (1999) J Womens Health Gend Based Med, 8, pp. 1043-1052Gise, L.H., Kase, N.G., Berkowitz, R.L., Contemporary issues in obstetrics and gynaecology (1988) The premenstrual syndromes, 2. , New York: Churchill LivingstoneHalbreich, U., Borenstein, J., Pearlstein, T., The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD) (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 1-23Johnson, S.R., The epidemiology and social impact of premenstrual symptoms (1987) Clin Obstet Gynecol, 30 (2), pp. 367-376American College of Obstetricians and Gynecologists. Premenstrual syndrome. Washington, DC: National Guideline Clearinghouse, 2000(1994) Diagnostic and statistical manual of mental disorders, , American Psychiatric Association, 4th ed. Washington, DC: American Psychiatric AssociationPerspectives on PMS/PMDD. Latin America Experts Group meeting2007 Jan 24-26Cancun, MexicoAndersch, B., Wenderstan, C., Hahn, L., Premenstrual complaints: 1. Prevalence of premenstrual symptoms in a Swedish urban population (1986) J Psychosom Obstet Gynaecol, 5, pp. 39-49Ramcharan, S., Love, E.J., Fick, G.H., The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors (1992) J Clin Epidemiol, 45 (4), pp. 377-392Di Giulio, G., Reissing, E.D., Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies (2006) J Psychosom Obstet Gynaecol, 27 (4), pp. 201-210Backström, T., Buchwald, S., The prevalence of PMS and PMDD and the awareness of associated terminology among women of reproductive age in European and Latin American countries [poster] (2005) World Congress of Human Reproduction, , Mar 10-13VeniceBackström, T., PMS and PMDD symptoms have a negative impact on daily life activities and quality of life among women in European and Latin American countries [oral presentation] (2005) World Congress of Human Reproduction, , Mar 10-13VeniceDean, B.B., Borenstein, J.E., A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome (2004) J Occup Environ Med, 46 (7), pp. 649-656PMS/PMDD negatively affects daily life activities. Pharmacoeconomics Outcomes News 2005476: 3-4Borenstein, J., Chiou, C.F., Dean, B., Estimating direct and indirect costs of premenstrual syndrome (2005) J Occup Environ Med, 47 (1), pp. 26-33Borenstein, J.E., Dean, B.B., Endicott, J., Health and economic impact of the premenstrual syndrome (2003) J Reprod Med, 48 (7), pp. 515-524Endicott, J., Nee, J., Harrison, W., Daily Record of Severity of Problems (DRSP): Reliability and validity (2006) Ach Womens Ment Health, 9 (1), pp. 41-49Halbreich, U., The etiology, biology, and evolving pathology of premenstrual syndromes (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 55-99Dalton, K., Dalton, M.E., Guthrie, K., Incidence of the premenstrual syndrome in twins (1987) BMJ, 295 (6605), pp. 1027-1028Johnson, S.R., Premenstrual syndrome, premenstrual dysphoric disorder, and be yond: A clinical primer for practitioners (2004) Obstet Gynecol, 104 (4), pp. 845-859Facchinetti, F., Genazzani, A.D., Martignoni, E., Neuroendocrine changes in luteal function in patients with premenstrual syndrome (1993) Clin Endocrinol Metab, 76 (5), pp. 1123-1127Schmidt, P.J., Nieman, L.K., Danaceau, M.A., Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome (1998) N Engl J Med, 338 (4), pp. 209-216Oelkers, W.K., Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure (1996) Steroids, 61 (4), pp. 166-171Chrousos, G.P., Torpy, D.J., Gold, P.W., Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: Clinical implications (1998) Ann Intern Med, 129 (3), pp. 229-240Cerin, A., Collins, A., Landgren, B.M., Hormonal and biochemical profiles of premenstrual syndrome: Treatment with essential fatty acids (1993) Acta Obstet Gynecol Scand, 72 (5), pp. 337-343Halbreich, U., Rojansky, N., Palter, S., Estrogen augments serotonergic activity in postmenopausal women (1995) Biol Psychiatry, 37 (7), pp. 434-441Matsumoto, A., Arai, Y., Osanai, M., Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats (1985) Neurosci Res, 2 (5), pp. 412-418McEwen BS, Alves SE, Bulloch K. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997485 Suppl. 7: 8-15De Ronchi, D., Muro, A., Marziani, A., Personality disorders and depressive symptoms in late luteal phase dysphoric disorder (2000) Psychother Psychosom, 69 (1), pp. 27-34Harlow, B.L., Cohen, L.S., Otto, M.W., Prevalence and predictors of depressive symptoms in older premenstrual women: The Harvard Study of Moods and Cycles (1999) Arch Gen Psychiatr, 56 (5), pp. 418-424Hendrick, V., Altshuler, L.L., Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter] (1998) J Clin Psychiatry, 59 (9), pp. 479-480Brawman-Mintzer, O., Shriqui, C., Biological basis of generalized anxiety disorder (1997) J Clin Psychiatry, 58 (SUPPL. 3), pp. 16-25Parry, B.L., Rosenthal, N.E., Tamarkin, L., Treatment of a patient with seasonal premenstrual syndrome (1987) Am J Psychiatry, 144 (6), pp. 762-766Praschak-Rieder, N., Willeit, M., Neumeister, A., Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder (2001) J Affect Disord, 63 (1-3), pp. 239-242Deuster, P.A., Adera, T., South-Paul, J., Biological, social, and behavioral factors associated with premenstrual syndrome (1999) Arch Fam Med, 8 (2), pp. 122-128Perkonigg, A., Yonkers, K.A., Pfister, H., Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder (2004) J Clin Psychiatry, 65 (10), pp. 1314-1322Campbell, E.M., Peterkin, D., O'Grady, K., Premenstrual symptoms in general practice patients: Prevalence and treatment (1997) J Reprod Med, 42 (10), pp. 637-646Severino, S.K., Moline, M.L., Premenstrual syndrome (1990) Obstet Gynecol Clin North Am, 17 (4), pp. 889-903Prior, J.C., Vigna, Y., Sciarretta, D., Conditioning exercise decreases premenstrual symptoms: A prospective, controlled 6-month trial (1987) Fertil Steril, 47 (3), pp. 402-408Steege, J.F., Blumenthal, J.A., The effects of aerobic exercise on premenstrual symp toms in middle-aged women: A preliminary study (1993) J Psychosom Res, 37 (2), pp. 127-133Freeman, E.W., Stout, A.L., Endicott, J., Treatment of premenstrual syndrome with a carbohydrate-rich beverage (2002) Int J Gynaecol Obstet, 77 (3), pp. 253-254Sayegh, R., Schiff, I., Wurtman, J., The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome (1995) Obstet Gynecol, 86 (4 PART 1), pp. 520-528Wyatt, K.M., Dimmock, P.W., Jones, P.W., Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review (1999) BMJ, 318 (7195), pp. 1375-1381Thys-Jacobs, S., Starkey, P., Bernstein, D., Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group (1998) Am J Obstet Gynecol, 179 (2), pp. 444-452Quaranta, S., Buscaglia, M.A., Meroni, M.G., Pilot study of the efficacy and safety of a modified-release magnesium 250mg tablet (Sincromag) for the treatment of premenstrual syndrome (2007) Clin Drug Investig, 27 (1), pp. 51-58Facchinetti, F., Borella, P., Sances, G., Oral magnesium successfully relieves premenstrual mood changes (1991) Obstet Gynecol, 78 (2), pp. 177-181Facchinetti, F., Sances, G., Borella, P., Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium (1991) Headache, 31 (5), pp. 298-301Berger, D., Schaffner, W., Schrader, E., Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS) (2000) Arch Gynecol Obstet, 264 (3), pp. 150-153Stevinson, C., Ernst, E., A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome (2000) BJOG, 107 (7), pp. 870-876Christensen, A.P., Oei, T.P., The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes (1995) J Affect Disord, 33 (1), pp. 57-63Hunter, M.S., Ussher, J.M., Browne, S., A randomized comparison of psychological (cognitive behavioural therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder (2002) Psychosom Obstet Gynaecol, 23 (3), pp. 193-199Hunter, M.S., Ussher, J.M., Cariss, M., Medical (Fluoxetine) and psychological (cognitive behavioural therapy) treatment for premenstrual dysphoric disorder: A study of treatment processes (2002) J Psychosom Res, 53 (3), pp. 811-817Rapkin, A., A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder (2003) Psychoneuroendocrinology, 28 (SUPPL. 3), pp. 39-53Smith, S., Rinehart, J.S., Ruddock, V.E., Treatment of premenstrual syndrome with alprazolam: Results of a double-blind, placebo-controlled, randomized crossover clinical trial (1987) Obstet Gynecol, 70 (1), pp. 37-43Freeman, E.W., Rickels, K., Sondheimer, S.J., A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome (1995) JAMA, 274 (1), pp. 51-57Evans, S.M., Haney, M., Levin, F.R., Mood and performance changes in women with premenstrual dysphoric disorder: Acute effects of alprazolam (1998) Neuropsychopharmacology, 19 (6), pp. 499-516Schmidt, P.J., Grover, G.N., Rubinow, D.R., Alprazolam in the treatment of premenstrual syndrome: A double-blind, placebo-controlled trial (1993) Arch Gen Psychiatry, 50 (6), pp. 467-473Landen, M., Eriksson, O., Sundblad, C., Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: A comparison of buspirone, nefazodone and placebo (2001) Psychopharmacology (Berl), 155 (3), pp. 292-298Bancroft, J., Boyle, H., Warner, P., The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes (1987) Clin Endocrinol (Oxf), 27 (2), pp. 171-182Brown, C.S., Ling, F.W., Andersen, R.N., Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial (1994) Obstet Gynecol, 84 (5), pp. 779-786Di Carlo, C., Palomba, S., Tommaselli, G.A., Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome (2001) Fertil Steril, 75 (2), pp. 380-384Freeman, E.W., Sondheimer, S.J., Rickels, K., Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study (1997) Psychopharmacol Bull, 33 (2), pp. 303-309Leather, A.T., Studd, J.W., Watson, N.R., The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: A placebo-controlled study (1999) Gynecol Endocrinol, 13 (1), pp. 48-55Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 199172 (2): 252A-FSundstrom, I., Nyberg, S., Bixo, M., Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen (1999) Acta Obstet Gynecol Scand, 78 (10), pp. 891-899West, C.P., Hillier, H., Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome (1994) Hum Reprod, 9 (6), pp. 1058-1063Wyatt, K.M., Dimmock, P.W., Ismail, K.M., The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: A meta analysis (2004) Bjog, 111 (6), pp. 585-593Deeny, M., Hawthorn, R., McKay Hart, D., Low dose danazol in the treatment of the premenstrual syndrome (1991) Postgrad Med J, 67 (787), pp. 450-454Hahn, P.M., Van Vugt, D.A., Reid, R.L., A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome (1995) Psychoneuroendocrinology, 20 (2), pp. 193-209Halbreich, U., Rojansky, N., Palter, S., Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes (1991) Fertil Steril, 56 (6), pp. 1066-1069Sarno Jr, A.P., Miller Jr, E.J., Lundblad, E.G., Premenstrual syndrome: Beneficial effects of periodic, low-dose danazol (1987) Obstet Gynecol, 70 (1), pp. 33-36Watts, J.F., Butt, W.R., Logan Edwards, R., A clinical trial using danazol for the treatment of premenstrual tension (1987) Br J Obstet Gynaecol, 94 (1), pp. 30-34Frackiewicz, E.J., Shiovitz, T.M., Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder (2001) J Am Pharm Assoc (Wash), 41 (3), pp. 437-447Dimmock, P.W., Wyatt, K.M., Jones, P.W., Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review (2000) Lancet, 356 (9236), pp. 1131-1136Cohen, L.S., Miner, C., Brown, E.W., Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries (2002) Obstet Gynecol, 100 (3), pp. 435-444Menkes, D.B., Taghavi, E., Mason, P.A., Fluoxetine's spectrum of action in premenstrual syndrome (1993) Int Clin Psychopharmacol, 8 (2), pp. 95-102Miner, C., Brown, E., McCray, S., Weekly luteal-phase dosing with enteric coated fluoxetine 90mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial (2002) Clin Ther, 24 (3), pp. 417-433Pearlstein, T.B., Stone, A.B., Lund, S.A., Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder (1997) J Clin Psychopharmacol, 17 (4), pp. 261-266Steiner, M., Romano, S.J., Babcock, S., The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder (2001) BJOG, 108 (5), pp. 462-468Steiner, M., Steinberg, S., Stewart, D., Fluoxetine in the treatment of premenstrual dysphoria: Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group (1995) N Engl J Med, 332 (23), pp. 1529-1534Stone, A.B., Pearlstein, T.B., Brown, W.A., Fluoxetine in the treatment of late luteal phase dysphoric disorder (1991) J Clin Psychiatry, 52 (7), pp. 290-293Su, T.P., Schmidt, P.J., Danaceau, M.A., Fluoxetine in the treatment of premenstrual dysphoria (1997) Neuropsychopharmacology, 16 (5), pp. 346-356Wood, S.H., Mortola, J.F., Chan, Y.F., Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study (1992) Obstet Gynecol, 80 (3 PART 1), pp. 339-344Cohen, L.S., Soares, C.N., Yonkers, K.A., Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial (2004) Psychosom Med, 66 (5), pp. 707-713Freeman, E.W., Rickels, K., Arredondo, F., Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant (1999) J Clin Psychopharmacol, 19 (1), pp. 3-8Freeman, E.W., Rickels, K., Sondheimer, S.J., Differential response to antidepres sants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial (1999) Arch Gen Psychiatry, 56 (10), pp. 932-939Freeman, E.W., Rickels, K., Sondheimer, S.J., Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder (2004) Am J Psychiatry, 161 (2), pp. 343-351Halbreich, U., Bergeron, R., Yonkers, K.A., Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder (2002) Obstet Gynecol, 100 (6), pp. 1219-1229Jermain, D.M., Preece, C.K., Sykes, R.L., Luteal phase sertraline treatment for premenstrual dysphoric disorder: Results of a double-blind, placebo-controlled, crossover study (1999) Arch Fam Med, 8 (4), pp. 328-332Pearlstein, T.B., Halbreich, U., Batzar, E.D., Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo (2000) J Clin Psychiatry, 61 (2), pp. 101-109Steiner, M., Hirschberg, A.L., Bergeron, R., Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder (2005) Am J Obstet Gynecol, 193 (2), pp. 352-360Yonkers, K.A., Gullion, C., Williams, A., Paroxetine as a treatment for premenstrual dysphoric disorder (1996) J Clin Psychopharmacol, 16 (1), pp. 3-8Yonkers, K.A., Halbreich, U., Freeman, E., Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group (1997) JAMA, 278 (12), pp. 983-988Yonkers, K.A., Halbreich, U., Freeman, E., Sertraline in the treatment of premenstrual dysphoric disorder (1996) Psychopharmacol Bull, 32 (1), pp. 41-46Freeman, E.W., Jabara, S., Sondheimer, S.J., Citalopram in PMS patients with prior SSRI treatment failure: A preliminary study (2002) J Womens Health Gend Based Med, 11 (5), pp. 459-464Wikander, I., Sundblad, C., Andersch, B., Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? (1998) J Clin Psychopharmacol, 18 (5), pp. 390-398Freeman, E.W., Sondheimer, S.J., Sammel, M.D., A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder (2005) J Clin Psychiatry, 66 (6), pp. 769-773Sundblad, C., Hedberg, M.A., Eriksson, E., Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial (1993) Neuropsychopharmacology, 9 (2), pp. 133-145Sundblad, C., Modigh, K., Andersch, B., Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo-controlled trial (1992) Acta Psychiatr Scand, 85 (1), pp. 39-47Ferguson, J.M., SSRI antidepressant medications: Adverse effects and tolerability (2001) Prim Care Companion J Clin Psychiatry, 3 (1), pp. 22-27Sundstrom-Poromaa, I., Bixo, M., Bjorn, I., Compliance to antidepressant drug therapy for treatment of premenstrual syndrome (2000) J Psychosom Obstet Gynaecol, 21 (4), pp. 205-211Graham, C.A., Sherwin, B.B., A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive (1992) J Psychosom Res, 36 (3), pp. 257-266Backstrom, T., Hansson-Malmstrom, Y., Lindhe, B.-A., Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations (1992) Contraception, 46, pp. 253-268O'Brien, P.M., Craven, D., Selby, C., Treatment of premenstrual syndrome by spironolactone (1979) Br J Obstet Gynaecol, 86 (2), pp. 142-147Burnet, R.B., Radden, H.S., Easterbrook, E.G., Premenstrual syndrome and spironolactone (1991) Aust N Z J Obstet Gynaecol, 31 (4), pp. 366-368Borenstein, J., Yu, H.T., Wade, S., Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life (2003) J Reprod Med, 48 (2), pp. 79-85Foidart, J.M., Wuttke, W., Bouw, G.M., A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel (2000) Eur J Contracept Reprod Health Care, 5 (2), pp. 124-134Freeman, E.W., Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder (2002) Eur J Contracept Reprod Health Care, 7 (SUPPL. 3), pp. 27-34,42-43Pearlstein, T.B., Bachmann, G.A., Zacur, H.A., Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation (2005) Contraception, 72 (6), pp. 414-421Sangthawan, M., Taneepanichskul, S., A comparative study of monophasic oral contraceptives containing either drospirenone 3mg or levonorgestrel 150 microg on premenstrual symptoms (2005) Contraception, 71 (1), pp. 1-7Sillem, M., Schneidereit, R., Heithecker, R., Use of an oral contraceptive containing drospirenone in an extended regimen (2003) Eur J Contracept Reprod Health Care, 8 (3), pp. 162-169Yonkers, K.A., Brown, C., Pearlstein, T.B., Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder (2005) Obstet Gynecol, 106 (3), pp. 492-501Sullivan, H., Furniss, H., Spona, J., Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity (1999) Fertil Steril, 72 (1), pp. 115-120Sulak, P.J., Scow, R.D., Preece, C., Hormone withdrawal symptoms in oral contraceptive users (2000) Obstet